| 2026-08-20 | Press release | Ionis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the Europe |
| 2026-08-19 | Earnings deck | Ionis 2Q26 Earnings Slides |
| 2026-08-06 | Press release | Bird L - Angelman Syndrome Program Update.pdf |
| 2026-07-29 | Press release | Ionis announces Dr. Frank Bennett, chief scientific officer, to retire |
| 2026-07-29 | Press release | Ionis reports second quarter 2026 financial results and highlights progress on key programs |
| 2026-07-15 | Press release | Ionis to hold second quarter 2026 financial results webcast |
| 2026-07-14 | Press release | Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduc |
| 2026-07-13 | Press release | Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome |
| 2026-07-09 | Press release | Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy |
| 2026-07-06 | Press release | Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome |
| 2026-06-25 | Presentation | Presentation |
| 2026-06-25 | Press release | Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the |
| 2026-06-24 | Press release | TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute |
| 2026-06-15 | Document | Presentation |
| 2026-06-11 | Press release | Tsao et al - Relationship Between PROMIS 29+2 and Home-Reported Outcomes (HROs) in a Population with Severe Hypertriglyc |
| 2026-06-08 | Press release | Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors |
| 2026-06-04 | Press release | Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia ( |
| 2026-05-30 | Press release | Fontana et al. - European Journal of Heart Failure Publication |
| 2026-05-28 | Press release | Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatme |
| 2026-05-21 | Press release | Ling et al. - Nucleic Acids Research Publication |
| 2026-05-14 | Press release | Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show red |
| 2026-05-06 | Document | Khella et al - Eplontersen in hereditary ATTR-polyneuropathy - Week 66 final analysis of the phase 3 NEURO-TTRansform st |
| 2026-05-01 | Press release | Ionis to present at upcoming investor conferences |
| Press release | Ionis reports first quarter 2026 financial results and highlights progress on key programs |
| 2026-04-28 | Press release | Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U. |
| Press release | Ionis to hold first quarter 2026 financial results webcast |
| 2026-03-25 | Press release | Marston N - Essence-TIMI 73b CCTA Trial - Effect on APOC3 Inhibition with Olezarsen on Coronary Atherosclerosis.pdf |
| 2026-03-23 | Press release | Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review |
| 2026-03-09 | Press release | Ionis announces changes to Board of Directors |
| 2026-02-26 | Press release | Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) |
| 2026-02-25 | Press release | Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs |
| 2026-02-19 | Press release | Ionis to present at upcoming investor conferences |
| 2026-02-17 | Press release | Ionis updates time for fourth quarter and full year 2025 financial results webcast |
| 2026-02-11 | Press release | Ionis to hold fourth quarter and full year 2025 financial results webcast |
| 2026-01-21 | Press release | DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE) |
| 2026-01-12 | Press release | Ionis well-positioned for continued momentum and substantial value creation in 2026 with two new independent launches an |
| 2026-01-07 | Press release | Ionis partner GSK announces positive topline results from B-Well 1 and B-Well 2 Phase 3 studies for bepirovirsen, a pote |
| 2026-01-06 | Press release | Ionis to present at 44th Annual J.P. Morgan Healthcare Conference |
| Press release | Ionis reports third quarter 2025 financial results and highlights progress on key programs |
| Press release | Ionis to hold third quarter 2025 financial results webcast |